Emergent BioSolutions Inc. (EBS)Healthcare | Drug Manufacturers - Specialty & Generic | Gaithersburg, United States | NYSE
7.67 USD
-0.35
(-4.304%) ⇩
(July 14, 2026, 10:02 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:30 a.m. EDT
The investment case for Emergent BioSolutions is currently broken by a severe multi-year structural decline. Despite a technically cheap valuation relative to book value, the company has lost roughly 76% of its value over the last nine years, with the most recent annual performance showing another significant drop. This is not a temporary correction; it is a fundamental deterioration where the market has repeatedly rejected the business's ability to generate returns, evidenced by negative equity growth and a trailing EPS that remains in the red. The lack of any dividend history confirms that capital preservation is not a priority for management, leaving shareholders exposed to pure price erosion. While the stock trades at a low multiple, this reflects the reality of a failing growth story rather than a margin of safety. The overwhelming options activity, which sees more buyers of puts than calls, validates the fear that the downtrend is far from over. Investors should avoid this security until there is clear, sustained evidence of a reversal in both revenue growth and profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.034261 |
| AutoARIMA | 0.049195 |
| AutoETS | 0.049611 |
| MSTL | 0.054397 |
| MSTL_126 | 0.146247 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.104 |
| Excess Kurtosis | -0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 111.757 |
| Revenue per Share | 12.8 |
| Market Cap | 395,485,600 |
| Forward P/E | 2.56 |
| Beta | 2.34 |
| Profit Margins | -1.27% |
| Website | https://www.emergentbiosolutions.com |
As of July 11, 2026, 5:30 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside speculation. Put open interest significantly exceeds call open interest across nearly all expirations, with heavy concentration in strikes below the current price (e.g., $7.00 and $8.00 puts). While there is some call volume at higher strikes ($15-$21), the dominant theme is hedging against further declines, suggesting a 'bearish' or defensive sentiment among retail and institutional traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15584421 |
| Address1 | 300 Professional Drive |
| Address2 | Suite 400 |
| All Time High | 137.61 |
| All Time Low | 1.42 |
| Ask | 7.83 |
| Ask Size | 900 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 721,630 |
| Average Daily Volume3 Month | 815,670 |
| Average Volume | 815,670 |
| Average Volume10Days | 721,630 |
| Beta | 2.339 |
| Bid | 7.81 |
| Bid Size | 200 |
| Board Risk | 3 |
| Book Value | 10.098 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.665 |
| Current Ratio | 4.288 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 8.01 |
| Day Low | 7.625 |
| Debt To Equity | 111.757 |
| Display Name | Emergent BioSolutions |
| Earnings Call Timestamp End | 1,777,582,800 |
| Earnings Call Timestamp Start | 1,777,582,800 |
| Earnings Growth | -0.938 |
| Earnings Quarterly Growth | -0.9 |
| Earnings Timestamp | 1,777,579,200 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | 166,700,000 |
| Ebitda Margins | 0.24631001 |
| Enterprise To Ebitda | 5.025 |
| Enterprise To Revenue | 1.238 |
| Enterprise Value | 837,586,304 |
| Eps Current Year | 0.95 |
| Eps Forward | 2.99 |
| Eps Trailing Twelve Months | -0.19 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 240 631 3203 |
| Fifty Day Average | 8.3762 |
| Fifty Day Average Change | -0.71119976 |
| Fifty Day Average Change Percent | -0.08490721 |
| Fifty Two Week Change Percent | 15.584421 |
| Fifty Two Week High | 14.06 |
| Fifty Two Week High Change | -6.3950005 |
| Fifty Two Week High Change Percent | -0.45483643 |
| Fifty Two Week Low | 5.62 |
| Fifty Two Week Low Change | 2.045 |
| Fifty Two Week Low Change Percent | 0.36387902 |
| Fifty Two Week Range | 5.62 - 14.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,163,601,000,000 |
| Float Shares | 49,384,363 |
| Forward Eps | 2.99 |
| Forward P E | 2.5635452 |
| Free Cashflow | 256,212,496 |
| Full Exchange Name | NYSE |
| Full Time Employees | 900 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.47487998 |
| Gross Profits | 321,400,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03848 |
| Held Percent Institutions | 0.86601996 |
| Implied Shares Outstanding | 51,596,296 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome#node/150 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Emergent BioSolutions Inc. |
| Market | us_market |
| Market Cap | 395,485,600 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_13627017 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -8,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 413,286,330 |
| Number Of Analyst Opinions | 2 |
| Open | 7.95 |
| Operating Cashflow | 148,000,000 |
| Operating Margins | 0.06791 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.38 |
| Phone | 240 631 3200 |
| Previous Close | 8.01 |
| Price Eps Current Year | 8.068421 |
| Price Hint | 2 |
| Price To Book | 0.7590612 |
| Price To Sales Trailing12 Months | 0.58434635 |
| Profit Margins | -0.01271 |
| Quick Ratio | 1.896 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.34500027 |
| Regular Market Change Percent | -4.3044324 |
| Regular Market Day High | 8.01 |
| Regular Market Day Low | 7.625 |
| Regular Market Day Range | 7.625 - 8.01 |
| Regular Market Open | 7.95 |
| Regular Market Previous Close | 8.01 |
| Regular Market Price | 7.665 |
| Regular Market Time | 1,784,037,776 |
| Regular Market Volume | 118,948 |
| Return On Assets | 0.03427 |
| Return On Equity | -0.01599 |
| Revenue Growth | -0.297 |
| Revenue Per Share | 12.8 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 51,596,296 |
| Shares Percent Shares Out | 0.199 |
| Shares Short | 10,265,965 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 9,760,594 |
| Short Name | Emergent BioSolutions Inc. |
| Short Percent Of Float | 0.2021 |
| Short Ratio | 10.15 |
| Source Interval | 15 |
| State | MD |
| Symbol | EBS |
| Target High Price | 12.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 12.0 |
| Total Cash | 160,300,000 |
| Total Cash Per Share | 3.107 |
| Total Debt | 584,600,000 |
| Total Revenue | 676,800,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.7272 |
| Two Hundred Day Average Change | -2.0621996 |
| Two Hundred Day Average Change Percent | -0.21200342 |
| Type Disp | Equity |
| Volume | 118,948 |
| Website | https://www.emergentbiosolutions.com |
| Zip | 20,879 |